# Bristol-Myers Squibb Company – Consensus ‘hold’ rating and 11.5% Upside Potential

- Link: https://www.directorstalkinterviews.com/bristol-myers-squibb-company-consensus-hold-rating-and-11.5-upside-potential/4121136287
- Published: 2023-12-15T12:03:34+00:00
- Author: Charlotte Edwards

**Bristol-Myers Squibb Company** with ticker code (BMY) now have 22 confirmed analysts
covering the stock with the consensus suggesting a rating of ‘hold’. The target 
price High/Low ranges between $83.34 and $38.89 with the average target price sitting
at $57.83. Now with the previous closing price of $51.86 this would imply there 
is now a potential upside of 11.5%. The 50 day MA is $52.53 and the 200 day moving
average is $61.58. The market cap for the company is 105.52B. The stock price is
currently at: $51.47 USD

 The potential market cap would be $117,670,295,943 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 13.06, revenue per share of $21.51
and a 5.59% return on assets.

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged
in the discovery, development, licensing, manufacturing, marketing, distribution,
and sale of biopharmaceutical products. It offers products for a range of therapeutic
classes, which include oncology, immunology, cardiovascular and hematology. Its 
pharmaceutical products include chemically synthesized or small molecule drugs and
products produced from biological processes, called biologics. Biologics are administered
to patients through injections or by infusion. Its products include Revlimid, Abecma,
Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti,
Reblozyl, Inrebic, Onureg, Zeposia, Camzyos, and Breyanzi. It also has a pipeline
of investigational medicines designed to target the common mutations associated 
with oncogenesis, including repotrectinib. Its products are sold to wholesalers,
distributors, pharmacies, retailers, hospitals, clinics, and government agencies.

Share on:
